MGNK.DE
Mologen AG [MGNK.DE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MGNK.DE Stock Summary
In the News
MGNK.DE Financial details
Company Rating
-
Market Cap
0
Income
-13.6M
Revenue
58K
Book val./share
-0.45
Cash/share
0.23
Dividend
-
Dividend %
-
Employees
43
Optionable
No
Shortable
Yes
Earnings
07 Nov 2019
P/E
-0.06
Forward P/E
-
PEG
0.01
P/S
-
P/B
-0.78
P/C
0.33
P/FCF
-
Quick Ratio
1.69
Current Ratio
1.97
Debt / Equity
-0
LT Debt / Equity
-
-
-
EPS (TTM)
-1.29
EPS next Y
-
EPS next Q
-
EPS this Y
-54.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-22.84%
Revenue last 5Y
202.65%
Revenue Q/Q
-
EPS Q/Q
-30.56%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-127%
ROE
409%
ROC
-2.45%
Gross Margin
-114%
Oper. Margin
-371%
Profit Margin
-390%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.068-0.08
52W High
-
52W Low
-
RSI
-
Rel Volume
1.35
Avg Volume
87.17K
Volume
117.97K
Perf Week
0%
Perf Month
0%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.077
Change
13.24%
MGNK.DE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2018-12-31
| Metric | History | 2014-12-31 | 2015-12-31 | 2016-12-31 | 2017-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|
| 2.01K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.01 | 0.01 | 0.01 | 0.26 | |
| Net income per share | -3.73 | -3.67 | -3.35 | -2.23 | -1.02 | |
| Operating cash flow per share | -3.41 | -2.69 | -3.07 | -2.21 | -1.17 | |
| Free cash flow per share | -3.43 | -2.71 | -3.08 | -2.21 | -1.17 | |
| Cash per share | 2.96 | 4.39 | 3.28 | 0.75 | 0.69 | |
| Book value per share | 2.9 | 3.48 | 1.89 | -0.56 | -0.08 | |
| Tangible book value per share | 2.86 | 3.45 | 1.88 | -0.56 | -0.08 | |
| Share holders equity per share | 2.9 | 3.48 | 1.89 | -0.56 | -0.08 | |
| Interest debt per share | 0 | 0 | 0.34 | 0.07 | 0.05 | |
| Market cap | 352.82K | 431.44K | 482.11K | 666.88K | 898.11K | |
| Enterprise value | -13.2M | -24.15M | -17.92M | -5.85M | -7.11M | |
| P/E ratio | -0.02 | -0.02 | -0.02 | -0.03 | -0.08 | |
| Price to sales ratio | 29.4 | 11.06 | 6.51 | 14.19 | 0.29 | |
| POCF ratio | -0.02 | -0.03 | -0.03 | -0.03 | -0.07 | |
| PFCF ratio | -0.02 | -0.03 | -0.02 | -0.03 | -0.07 | |
| P/B Ratio | 0.03 | 0.02 | 0.04 | -0.14 | -0.95 | |
| PTB ratio | 0.03 | 0.02 | 0.04 | -0.14 | -0.95 | |
| EV to sales | -1.1K | -619.3 | -242.11 | -124.41 | -2.33 | |
| Enterprise value over EBITDA | 0.78 | 1.18 | 0.87 | 0.31 | 0.63 | |
| EV to operating cash flow | 0.85 | 1.6 | 0.93 | 0.31 | 0.52 | |
| EV to free cash flow | 0.84 | 1.59 | 0.93 | 0.31 | 0.52 | |
| Earnings yield | -48.4 | -47.6 | -43.57 | -28.91 | -13.23 | |
| Free cash flow yield | -44.49 | -35.19 | -40.05 | -28.72 | -15.25 | |
| Debt to equity | 0 | 0 | 0.18 | 0 | -0.01 | |
| Debt to assets | 0 | 0 | 0.1 | 0 | 0 | |
| Net debt to EBITDA | 0.8 | 1.2 | 0.89 | 0.35 | 0.71 | |
| Current ratio | 8.36 | 3.77 | 2.88 | 1.07 | 1.97 | |
| Interest coverage | 0 | 0 | -1.17K | -32.37 | -19.35 | |
| Income quality | 0.91 | 0.73 | 0.92 | 0.99 | 1.15 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 99 | 39.69 | 23.32 | 44.57 | 0.63 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0.01 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0 | 0 | 0 | |
| Capex to revenue | -7.75 | -2.44 | -0.77 | -0.7 | 0 | |
| Capex to depreciation | -0.85 | -0.79 | -0.14 | -0.67 | -0.26 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 15.6 | 16.94 | 11.95 | 5.31 | 1.36 | |
| ROIC | -1.29 | -1.05 | -1.5 | 3.85 | 12.1 | |
| Return on tangible assets | -1.15 | -0.78 | -0.98 | -2.38 | -1.27 | |
| Graham Net | 2.58 | 3.16 | 1.76 | -0.74 | -0.17 | |
| Working capital | 12.87M | 19.1M | 13.9M | 559K | 4.59M | |
| Tangible asset value | 13.09M | 19.33M | 11.8M | -4.89M | -946K | |
| Net current asset value | 12.86M | 19.09M | 11.78M | -4.92M | -963K | |
| Invested capital | 0 | 0 | 0.18 | 0 | -0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 934.5K | 3.85M | 6.46M | 5.47M | 3.52M | |
| Average inventory | 31.5K | 29K | 20.5K | 14.5K | 358.5K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 55.25 | 211.82 | 202.33 | 164.68 | 147.59 | |
| Days of inventory on hand | 1.26 | 0.93 | 0.4 | 0.6 | 39.19 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 6.61 | 1.72 | 1.8 | 2.22 | 2.47 | |
| Inventory turnover | 289.57 | 393.25 | 906.15 | 609.5 | 9.31 | |
| ROE | -1.28 | -1.05 | -1.77 | 3.96 | 12.57 | |
| Capex per share | -0.02 | -0.02 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2019-09-30 for Q3
| Metric | History | 2018-09-30 | 2018-12-31 | 2019-03-31 | 2019-06-30 | 2019-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.01 | 0 | 0 | 0.01 | 0 | |
| Net income per share | -0.48 | -0.29 | -0.39 | -0.36 | -0.25 | |
| Operating cash flow per share | -0.38 | -0.41 | -0.44 | -0.39 | -0.22 | |
| Free cash flow per share | -0.38 | -0.41 | -0.44 | -0.39 | -0.22 | |
| Cash per share | 0.45 | 0.87 | 0.67 | 0.52 | 0.23 | |
| Book value per share | -0.83 | -0.1 | -0.27 | -0.23 | -0.45 | |
| Tangible book value per share | -0.83 | -0.1 | -0.27 | -0.23 | -0.45 | |
| Share holders equity per share | -0.83 | -0.1 | -0.27 | -0.23 | -0.45 | |
| Interest debt per share | 0.02 | 0.02 | 0 | 0.58 | 0.02 | |
| Market cap | 707.37K | 707.37K | 749.27K | 876.72K | 953.18K | |
| Enterprise value | -3.45M | -7.3M | -5.73M | 1.31M | -1.87M | |
| P/E ratio | -0.04 | -0.07 | -0.05 | -0.05 | -0.08 | |
| Price to sales ratio | 15.05 | 0 | 0 | 15.12 | 0 | |
| POCF ratio | -0.2 | -0.19 | -0.18 | -0.2 | -0.35 | |
| PFCF ratio | -0.2 | -0.19 | -0.18 | -0.2 | -0.35 | |
| P/B Ratio | -0.09 | -0.75 | -0.29 | -0.34 | -0.17 | |
| PTB ratio | -0.09 | -0.75 | -0.29 | -0.34 | -0.17 | |
| EV to sales | -73.46 | 0 | 0 | 22.67 | 0 | |
| Enterprise value over EBITDA | 0.81 | 2.92 | 1.51 | -0.34 | 0.68 | |
| EV to operating cash flow | 0.99 | 1.96 | 1.35 | -0.3 | 0.68 | |
| EV to free cash flow | 0.99 | 1.96 | 1.35 | -0.3 | 0.68 | |
| Earnings yield | -6.27 | -3.76 | -5.06 | -4.68 | -3.19 | |
| Free cash flow yield | -4.94 | -5.27 | -5.67 | -5.04 | -2.89 | |
| Debt to equity | 0 | -0.01 | 0 | -2.5 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0.84 | 0 | |
| Net debt to EBITDA | 0.97 | 3.2 | 1.71 | -0.11 | 1.02 | |
| Current ratio | 0.9 | 1.97 | 1.49 | 1.9 | 1.15 | |
| Interest coverage | -28.57 | -17.12 | 0 | -16.86 | -12.15 | |
| Income quality | 0.79 | 1.4 | 1.12 | 1.08 | 0.91 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.09 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.4 | -0.36 | 0 | 0 | -0.03 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3 | 0.82 | 1.54 | 1.35 | 1.58 | |
| ROIC | 0.56 | 2.69 | 0 | -0.97 | 0.5 | |
| Return on tangible assets | -0.78 | -0.28 | -0.48 | -0.54 | -0.71 | |
| Graham Net | -0.96 | -0.21 | -0.42 | -0.34 | -0.54 | |
| Working capital | -618K | 4.59M | 2.12M | 3.56M | 534K | |
| Tangible asset value | -7.6M | -946K | -2.62M | -2.56M | -5.57M | |
| Net current asset value | -7.62M | -963K | -4.06M | -2.72M | -5.72M | |
| Invested capital | 0 | -0.01 | 0 | -2.5 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 3.62M | 3.23M | 1.32M | 1.25M | 2.39M | |
| Average inventory | 706.5K | 703.5K | 350.5K | 348.5K | 697K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 164.26 | 284.21 | 0 | 115.43 | 279.6 | |
| Days of inventory on hand | 30.29 | 75.47 | 0 | 32.17 | 85.81 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.55 | 0.32 | 0 | 0.78 | 0.32 | |
| Inventory turnover | 2.97 | 1.19 | 0 | 2.8 | 1.05 | |
| ROE | 0.58 | 2.82 | 1.45 | 1.6 | 0.55 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
MGNK.DE Frequently Asked Questions
What is Mologen AG stock symbol ?
Mologen AG is a DE stock and trading under the symbol MGNK.DE
What is Mologen AG stock quote today ?
Mologen AG stock price is $0.077 today.
Is Mologen AG stock public?
Yes, Mologen AG is a publicly traded company.
Company Profile
- Volume Average 87.17K
- Employee 43
- CEO Prof. Burghardt Wittig
- Headquarters Berlin,DE
- IPO Date 2022-02-01
-
Website
https://www.mologen.com 
Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and human immunodeficiency virus (HIV). The company's lead product is Lefitolimod, an immunotherapeutic agent, which is in Phase III study for the treatment of metastatic colorectal cancer; Phase II trial for the treatment of small-cell lung cancer; and Phase Ib/IIa study of lefitolimod in HIV infected patients under antiretroviral therapy through collaborations with the Aarhus University Hospital in Denmark. Its lead product Lefitolimod is also under Phase I combination study with the checkpoint inhibitor Yervoy to treat advanced solid tumors in collaboration with MD Anderson Cancer Center at the University of Texas, the United States. In addition, the company is involved in the development of EnanDIM molecules, which are under pre-clinical development for cancer/anti-infective therapies; and MGN1601, a cell based therapeutic vaccine, which has completed Phase I/II trial for the treatment of renal cancer. Mologen AG was founded in 1998 and is headquartered in Berlin, Germany.
